Types of SELEX and Tips for Aptamer Selection Success

Unmodified aptamers face significant stability challenges in vivo. RNA aptamers have half-lives of only seconds in humans due to rapid degradation. DNA aptamers last longer (minutes) but still face degradation. The FDA-approved Macugen aptamer was heavily modified with PEGylation, fluorine atoms, and methoxy groups to improve stability. Most aptamers used in research include inverted dT at the 3' end to prevent exonuclease degradation, extending their half-life significantly.

Unmodified RNA aptamers are rapidly degraded by cellular nucleases, resulting in very short half-lives. Chemists have developed modifications to increase stability: locked nucleic acid (LNA) modifications can extend half-life up to 53-72 hours. However, excessive PEGylation (adding polyethylene glycol chains) can cause toxicity issues. A balance must be struck between achieving sufficient half-life for therapeutic effectiveness and avoiding immune responses that come with too many modifications.

Unmodified aptamers are susceptible to nuclease-mediated degradation leading to very short in vivo half-lives (typically less than 10 minutes). Therefore, most aptamers in clinical development feature chemical modifications to improve nuclease resistance and pharmacokinetic properties—for example, Macugen is pegylated and conjugated to polyethylene glycol (PEG) to extend its half-life in vivo. Aptamers can act as antagonists to block protein-protein or receptor-ligand interactions, agonists to activate receptors, or as cell-specific delivery systems. All aptamers currently in clinical development are inhibitors that disrupt the function of a protein. Additionally, aptamers can be designed to act as RNA decoys that compete with natural RNA sequences representing targets of RNA-binding proteins, sequestering their interaction.

Oligonucleotide stability is achieved through chemical modifications: (1) Sugar modifications (2'-O-methylation, 2'-fluoro) protect against nucleases; (2) Backbone modifications (phosphorothioates, methylphosphonates) enhance resistance; (3) Nucleobase modifications reduce immunogenicity. Different modifications affect stability, pharmacokinetics, and cellular uptake differently. The choice of modification strategy depends on the therapeutic application and target tissue.

The recommendation is to avoid including unnecessary modifications, as this complicates clinical development. For RNA aptamers, modifying all pyrimidines with 2' fluoro provides significant stability improvements, while modifying only a few purines does not yield the same benefit. More modifications that do not disrupt function are generally better. For siRNA, modifications can reduce dosing frequency, offsetting costs through reduced administration. Target selection focuses on cytoplasmic mRNA targets, with endosomal escape remaining a critical challenge for nuclear targets. 2' fluoro pyrimidines and purines are safe in oligonucleotides despite being toxic as free triphosphates, because degradation releases minimal free triphosphate. Achieving 4+ grams from 1 millimole synthesis represents a significant advancement, primarily through polymeric support use. When using novel modifications, sponsors become responsible for the entire supply chain including regulatory compliance and manufacturing quality.

Aptamers serve diverse therapeutic functions: antagonistic aptamers inhibit disease progression (PSMA aptamers reducing metastasis in prostate cancer models at 0.1 mg/kg IV); agonistic aptamers activate immune responses by targeting co-stimulatory receptors (41BB, OX40, CD28), with multimerization switching behavior from antagonist to agonist; aptamers enable drug delivery by conjugating to siRNAs, small molecules, and proteins. Currently, only Macugen (VEGF-165 aptamer) is FDA-approved for age-related macular degeneration. Challenges include nucleic acid degradation (addressed by 2'-fluoro, amino, methyl modifications), renal clearance (aptamers below 30-50 kDa cutoff), and toxicity concerns including non-specific protein binding and PEG-induced immune responses. Multiple aptamers remain in clinical development phases I-III for cancer, inflammation, cardiovascular diseases, and immunological disorders.

Aptamers are single-stranded DNA or RNA molecules that function as 'chemical antibodies' with unique advantages over traditional antibodies including smaller size for better tissue penetration, easier in vitro production without animal hosts, and longer shelf life at room temperature; however, they face challenges with rapid nuclease degradation requiring chemical modifications like locked nucleic acids to extend half-life, and they bind to targets through 3D structural pockets rather than simple hybridization, making them valuable tools for targeted drug delivery, cancer therapy, and multiplexed diagnostics.

Aptamers are single-stranded nucleic acid or peptide molecules generated through systematic selection, existing as DNA, RNA, or peptide variants. They bind targets through structure-based recognition achieving nanomolar-to-picomolar affinity, offering advantages over antibodies including easier production, thermal stability, non-immunogenicity, and ability to target toxic ligands. The global aptamer market has grown from million-dollar to billion-dollar status, with FDA-approved Macugen demonstrating clinical viability. Applications span diagnostics (detecting pathogens including SARS-CoV-2, Salmonella, Plasmodium, and various viruses), targeted drug delivery (conjugated to PSMA for prostate cancer), virology (inhibiting HIV through CD4, CCR5, Tat, and gp120 targeting), and neurological disorders (addressing Alzheimer's, Parkinson's, prion diseases, and brain tumors). This versatility positions aptamers as foundational tools bridging basic research, diagnostics, and therapeutics across diverse biomedical challenges.

Currently, the only FDA-approved aptamer drug is Macugen (an RNA aptamer to VEGF) used for age-related macular degeneration, though it requires intravitreal injection. Several other aptamers are in Phase 2 clinical trials for conditions including coagulation disorders (factor IXa inhibitors). For diagnostics, no FDA-approved aptamer-based tests exist yet despite thousands of aptamers being developed. The thrombin aptamer (a symmetric G-rich DNA forming G-quartets) costs approximately $30 for milligram quantities, making it cheaper than custom-made aptamers.

Aptamers have diverse applications in therapy and diagnostics. In cancer treatment, aptamers can be conjugated to cytotoxic agents like doxorubicin and targeted to cancer cells. For infectious diseases, aptamers can neutralize bacterial toxins by competitive binding, such as alpha-toxin from Staphylococcus aureus. In diagnostics, aptamers detect pathogens (Listeria, Staphylococcus aureus, Salmonella), bacterial components (endotoxins, peptidoglycan), and viral proteins (HIV, influenza). Toxin B from Clostridioides difficile, responsible for 30% of healthcare-associated infections, has been targeted by aptamers for diagnostic detection in fecal samples using ELISA-like assays with horseradish peroxidase for colorimetric detection.

The in silico analysis workflow for aptamers involves: (1) Identifying aptamer sequences, (2) Generating secondary structures using tools like RNAfold, (3) Evaluating structural stability under different conditions (temperature, sodium, magnesium concentrations), (4) Generating tertiary structures using tools like RNAComposer, (5) Evaluating ligand interactions through molecular docking. This systematic approach allows researchers to assess aptamer stability and binding characteristics before experimental validation.

In silico triaging involves computational modeling to evaluate aptamer candidates before experimental testing. This approach helps identify whether an aptamer possesses sufficient flexibility to undergo useful conformational changes upon target binding that could generate electrochemical signals. Key considerations include checking for secondary structures that might cause aptamers to hybridize with themselves rather than binding to targets, which would weaken sensor signals. Additionally, modeling helps assess whether adequate spacing exists between the surface attachment point (such as a thiol bond to gold) and the aptamer's binding site to prevent structural disruption. This computational screening reduces experimental failure rates by eliminating unsuitable candidates early in the development process.

SELEX (Systematic Evolution of Ligands by EXponential enrichment) is an in vitro evolution method that accelerates molecular selection. The process involves: (1) chemical synthesis of diverse DNA libraries, (2) enrichment and amplification of molecules binding to predetermined targets, (3) selection of sequences forming complex 3D structures complementary to targets. Targets range from small molecules to proteins to entire cells. The key distinction is between base complementarity (A-T, G-C matching) and surface complementarity (complex 3D structural matching). Once a binding sequence is identified, it can be chemically synthesized and used therapeutically as an aptamer.

In silico methods for aptamer design involve using databases of aptamers and computational approaches to predict binding to target proteins. The process involves virtual screening of aptamer databases against target proteins, followed by molecular dynamics analysis to identify the best binders. This is followed by experimental verification using technologies such as MSD (Meso Scale Discovery) to confirm binding. In silico methods allow visualization of where aptamers bind to targets, which can help in selection and improve the success rate of experimental approaches.

Aptamers are highly structured, short single-stranded DNA or RNA oligonucleotides discovered in 1990, named from Latin 'aptus' (to fit) and Greek 'meis' (a part). They offer advantages over antibodies including complex 3D structures for high affinity/specificity, small size (<5 nm) for tissue penetration, and ease of chemical modification. SELEX (Systematic Evolution of Ligands by Exponential Enrichment) is the iterative selection process: starting with a double-stranded DNA library containing a variable region (10-90 nucleotides), converting to single-stranded RNA with modified nucleotides for stability, combining with targets, and enriching binders through multiple rounds of selection, washing, and amplification. Advances include negative selection for specificity, alternative amplification methods (emulsion PCR, droplet digital PCR), and high-throughput sequencing integration.